Literature DB >> 34299149

MicroRNAs in Epithelial-Mesenchymal Transition Process of Cancer: Potential Targets for Chemotherapy.

Fu Peng1, Huali Fan1, Sui Li1, Cheng Peng2, Xiaoqi Pan2.   

Abstract

In the last decades, a kind of small non-coding RNA molecules, called as microRNAs, has been applied as negative regulators in various types of cancer treatment through down-regulation of their targets. More recent studies exert that microRNAs play a critical role in the EMT process of cancer, promoting or inhibiting EMT progression. Interestingly, accumulating evidence suggests that pure compounds from natural plants could modulate deregulated microRNAs to inhibit EMT, resulting in the inhibition of cancer development. This small essay is on the purpose of demonstrating the significance and function of microRNAs in the EMT process as oncogenes and tumor suppressor genes according to studies mainly conducted in the last four years, providing evidence of efficient target therapy. The review also summarizes the drug candidates with the ability to restrain EMT in cancer through microRNA regulation.

Entities:  

Keywords:  cancer; drug candidates; epithelial–mesenchymal transition; miRNA

Year:  2021        PMID: 34299149     DOI: 10.3390/ijms22147526

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  7 in total

1.  SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma.

Authors:  Weiqiang You; Jia Ke; Yufeng Chen; Zerong Cai; Ze-Ping Huang; Peishan Hu; Xiaojian Wu
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

Review 2.  Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology.

Authors:  Jianbo Zhou; Li Wang; Cheng Peng; Fu Peng
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 3.  Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).

Authors:  Sui Li; Xiaofang Xie; Fu Peng; Junrong Du; Cheng Peng
Journal:  Int J Oncol       Date:  2022-07-07       Impact factor: 5.884

Review 4.  New Advances in Targeted Therapy of HER2-Negative Breast Cancer.

Authors:  Junsha An; Cheng Peng; Xiaofang Xie; Fu Peng
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

5.  Maackiain Modulates miR-374a/GADD45A Axis to Inhibit Triple-Negative Breast Cancer Initiation and Progression.

Authors:  Fu Peng; Li Wang; Liang Xiong; Hailin Tang; Junrong Du; Cheng Peng
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

6.  MiRNA-148a inhibits cell growth and drug resistance by regulating WNT10a expression in renal cell carcinoma.

Authors:  Yongsheng Chen; Wenhua Liu; Dechao Li; Yan Cao; Wentao Wang; Changfu Li; Ruihua An
Journal:  Transl Androl Urol       Date:  2022-07

7.  Potential Anti-Metastatic Role of the Novel miR-CT3 in Tumor Angiogenesis and Osteosarcoma Invasion.

Authors:  Lavinia Raimondi; Alessia Gallo; Nicola Cuscino; Angela De Luca; Viviana Costa; Valeria Carina; Daniele Bellavia; Matteo Bulati; Riccardo Alessandro; Milena Fini; Pier Giulio Conaldi; Gianluca Giavaresi
Journal:  Int J Mol Sci       Date:  2022-01-09       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.